METTL3 acts as an oncogene in NSCLC by mediating Bcl-2 mRNA m6A modification, suggesting that targeting METTL3 may be an effective therapeutic strategy for the clinical management of NSCLC [45]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.